Suven Life Science has received a patent each by Europe, Japan and New Zealand for a drug which is used in treating neuro degenerative diseases.

Suven Life has said in a BSE filing that “one process patent from Europe, one process patent from Japan and one process patent from New Zealand corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases.”

According to the company the patents are valid till 2034.

Read Equitypandit’s Technical Analysis on Nifty Pharma